Hanism of activation and insights into differential inhibitor sensitivity. Most cancers Cell 11(three):21727. sixty two. Chang S, et al. (2012) Design, synthesis, and organic analysis of novel conformationally constrained 519187-97-4 custom synthesis inhibitors concentrating on AG3340 Metabolic Enzyme/Protease epidermal growth variable receptor threonine790 methionine790 mutant. J Med Chem fifty five(six):2711723. 63. Dey JH, et al. (2010) Concentrating on fibroblast development issue receptors blocks PI3KAKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Most cancers Res 70(10):4151162.sixty four. Cole C, et al. (2010) Inhibition of FGFR2 and FGFR1 will increase cisplatin sensitivity in TMC435 サイト Ovarian most cancers. Cancer Biol Ther ten(five):49504. sixty five. Sewell JM, Macleod KG, Ritchie A, Smyth JF, Langdon SP (2002) Targeting the EGF receptor in ovarian cancer with all the tyrosine kinase inhibitor ZD 1839 (“Iressa”) Br J Most cancers 86(3):45662. 66. Aref AR, et al. (2013) Screening therapeutic EMT blocking agents in the three-dimensional microenvironment. Integr Biol (Camb) five(two):38189. 67. Itoh N (2007) The Fgf households in human beings, mice, and zebrafish: Their evolutional procedures and roles in growth, metabolic process, and ailment. Biol Pharm Bull thirty(10): 1819825. sixty eight. Turkington RC, et al. (2014) Fibroblast progress aspect receptor four (FGFR4): A targetable regulator of drug resistance in colorectal cancer. Cell Death Dis 5:e1046. sixty nine. Miura S, et al. (2012) Fibroblast expansion variable 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Most cancers twelve(56): 15. 70. Pel z-Garc A, et al. (2013) FGFR4 role in epithelial-mesenchymal changeover and its therapeutic worth in colorectal most cancers. PLoS One particular 8(five):e63695. 71. Agarwal D, et al.; kConFab Investigators; Australian Ovarian Cancer Analyze Group; GENICA Network; TNBCC (2014) FGF receptor genes and breast most cancers susceptibility: Success in the Breast Most cancers Affiliation Consortium. Br J Cancer one hundred ten(four):1088100. 72. Cheng AL, Shen YC, Zhu AX (2011) Concentrating on fibroblast growth variable receptor signaling in hepatocellular carcinoma. Oncology eighty one(5-6):37280. 73. French DM, et al. (2012) Concentrating on FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 7(5):e36713. seventy four. Ito F (2011) Foreword. Target treatment for cancer: Anti-cancer medicines focusing on growthfactor signaling molecules. Biol Pharm Bull 34(twelve):1773. 75. Slattery ML, et al. (2013) Associations with expansion element genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast most cancers risk and survival: The Breast Most cancers Overall health Disparities Examine. Breast Cancer Res Handle a hundred and forty(three):58701. seventy six. Kono SA, Marshall ME, Ware KE, Heasley LE (2009) The fibroblast development element receptor signaling pathway like a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung most cancers. Drug Resist Updat twelve(4-5):9502. 77. Tai AL, et al. (2006) Co-overexpression of fibroblast development component 3 and epidermal growth element receptor is correlated with all the advancement of nonsmall cell lung carcinoma. Most cancers 106(1):14655. seventy eight. Terai H, et al. (2013) Activation on the FGF2-FGFR1 autocrine pathway: A novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Most cancers Res 11(7):75967. seventy nine. Ware KE, et al. (2010) Speedily acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell strains as a result of de-repression of FGFR2 and FGFR3 expression. PLoS One particular five(eleven):e14117. 80. Herrera-Abreu MT, et al. (2013) Parallel RNA interference screens establish EGFR activation as an escape system in FGFR3-mutant.
